Journal
MICROSCOPY AND MICROANALYSIS
Volume 28, Issue 5, Pages 1679-1686Publisher
OXFORD UNIV PRESS
DOI: 10.1017/S1431927622000708
Keywords
alpha-2 adrenergic receptor agonist; dexmedetomidine; hypotension; imaging resolution improvement; intravital imaging
Categories
Funding
- Basic Science Research Program [2019R1A2C2084122]
- MRC through the National Research Foundation of Korea (NRF) [2018R1A5A2020732]
- Ministry of Science ICT (MSIT)
- Ministry of Trade, Industry & Energy (MOTIE) under the Industrial Technology Innovation Program [20000843]
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI18C2391]
- Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea [2022IP0053]
Ask authors/readers for more resources
This study demonstrates that administering dexmedetomidine to mice can reduce fluorescence fluctuations caused by respiration, improving the quality and resolution of intravital fluorescence imaging.
Among intravital imaging instruments, the intravital two-photon fluorescence excitation microscope has the advantage of enabling real-time 3D fluorescence imaging deep into cells and tissues, with reduced photobleaching and photodamage compared with conventional intravital confocal microscopes. However, excessive motion of organs due to involuntary movement such as breathing may result in out-of-focus images and severe fluorescence intensity fluctuations, which hinder meaningful imaging and analysis. The clinically approved alpha-2 adrenergic receptor agonist dexmedetomidine was administered to mice during two-photon fluorescence intravital imaging to alleviate this problem. As dexmedetomidine blocks the release of the neurotransmitter norepinephrine, pain is suppressed, blood pressure is reduced, and a sedation effect is observed. By tracking the quality of focus and stability of detected fluorescence in two-photon fluorescence images of fluorescein isothiocyanate-sensitized liver vasculature in vivo, we demonstrated that intravascular dexmedetomidine can reduce fluorescence fluctuations caused by respiration on a timescale of minutes in mice, improving image quality and resolution. The results indicate that short-term dexmedetomidine treatment is suitable for reducing involuntary motion in preclinical intravital imaging studies. This method may be applicable to other animal models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available